migrastatin has been researched along with Neoplasms* in 2 studies
1 review(s) available for migrastatin and Neoplasms
| Article | Year |
|---|---|
The Therapeutic Potential of Migrastatin-Core Analogs for the Treatment of Metastatic Cancer.
Tumor metastasis is a complex process in which cells detach from the primary tumor and colonize a distant organ. Metastasis is also the main process responsible for cancer-related death. Despite the enormous efforts made to unravel the metastatic process, there is no effective therapy, and patients with metastatic tumors have poor prognosis. In this regard, there is an urgent need for new therapeutic tools for the treatment of this disease. Small molecules with the capacity to reduce cell migration could be used to treat metastasis. Migrastatin-core analogs are naturally inspired macrocycles that inhibit pathological cell migration and are able to reduce metastasis in animal models. Migrastatin analogs can be synthesized from a common advanced intermediate. Herein we present a review of the synthetic approaches that can be used to prepare this key intermediate, together with a review of the biological activity of migrastatin-core analogs and current hypotheses concerning their mechanism of action. Topics: Animals; Antineoplastic Agents; Biological Products; Cell Line, Tumor; Cell Movement; Drug Evaluation, Preclinical; Humans; Macrolides; Neoplasm Metastasis; Neoplasms; Piperidones | 2017 |
1 other study(ies) available for migrastatin and Neoplasms
| Article | Year |
|---|---|
Migrastatin, a new inhibitor of tumor cell migration from Streptomyces sp. MK929-43F1. Taxonomy, fermentation, isolation and biological activities.
A new compound, migrastatin, was isolated from a cultured broth of Streptomyces sp. MK929-43F1, as an inhibitor of tumor cell migration. It was purified by column chromatographies on silica gel and Sephadex LH-20 and HPLC. Migrastatin has the molecular formula of C27H39NO7 consisting of 14-membered macrolide and glutarimide moiety. It inhibited spontaneous migration of human esophageal cancer EC17 cells. Migration inhibitory activity of migrastatin was not dependent on cytotoxicity or inhibition of protein synthesis. Topics: Animals; Antibiotics, Antineoplastic; Cell Movement; Cell Survival; Chemotaxis; DNA; Drug Screening Assays, Antitumor; Esophageal Neoplasms; Fermentation; Humans; Lactones; Macrolides; Melanoma, Experimental; Mice; Neoplasms; Piperidones; Protein Biosynthesis; RNA; Streptomyces; Tumor Cells, Cultured; Wound Healing | 2000 |